Search
GC-373
go.drugbank.com/drugs/DB15797ExperimentalIt is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalThe synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.
ZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalAs of August, 2020 the candidate is in Phase II clinical trials[A219758].
Amcipatricin
go.drugbank.com/drugs/DB12333InvestigationalAmcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Althou...
Amniotic Epithelial Cells
go.drugbank.com/drugs/DB15868InvestigationalAmniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell ...
VPM1002
go.drugbank.com/drugs/DB15801InvestigationalAs of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other
IL-2 pDNA
go.drugbank.com/drugs/DB05935ExperimentalVical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.
TAK-475
go.drugbank.com/drugs/DB05317InvestigationalTAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.